Prentiss Smith & Co. Inc. Sells 500 Shares of Pfizer Inc. (NYSE:PFE)

Prentiss Smith & Co. Inc. lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,323 shares of the biopharmaceutical company’s stock after selling 500 shares during the quarter. Prentiss Smith & Co. Inc.’s holdings in Pfizer were worth $499,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Investment Advisory Services Inc. TX ADV grew its position in Pfizer by 1.6% during the third quarter. Investment Advisory Services Inc. TX ADV now owns 20,097 shares of the biopharmaceutical company’s stock worth $667,000 after buying an additional 325 shares in the last quarter. Trifecta Capital Advisors LLC grew its position in Pfizer by 3.7% during the third quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 325 shares in the last quarter. Powers Advisory Group LLC boosted its holdings in Pfizer by 2.4% during the third quarter. Powers Advisory Group LLC now owns 13,759 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 329 shares in the last quarter. Confluence Wealth Services Inc. boosted its holdings in Pfizer by 0.5% during the third quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock valued at $2,158,000 after purchasing an additional 342 shares in the last quarter. Finally, Carr Financial Group Corp boosted its holdings in Pfizer by 3.3% during the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 355 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock traded down $1.01 during mid-day trading on Thursday, reaching $25.26. The company had a trading volume of 47,041,425 shares, compared to its average volume of 41,958,969. Pfizer Inc. has a fifty-two week low of $25.23 and a fifty-two week high of $40.37. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company has a market cap of $143.04 billion, a P/E ratio of 70.17, a P/E/G ratio of 1.19 and a beta of 0.61. The business has a fifty day simple moving average of $27.05 and a 200 day simple moving average of $28.50.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.14 earnings per share. On average, equities research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.65%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio is presently 466.67%.

Analysts Set New Price Targets

PFE has been the topic of a number of recent research reports. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.